Differentiating among incretin therapies: A multiple-target approach to type 2 diabetes

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 5, 2012, Pages 510-524

  Cornell, S ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

dipeptidyl peptidase 4 inhibitor; exenatide; glucagon like peptide 1 receptor agonists; incretin therapy; liraglutide; type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; EXENDIN 4; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN DETEMIR; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMINO ACID SUBSTITUTION; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; COMORBIDITY; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DYSPEPSIA; FATTY ACID BLOOD LEVEL; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HOMOEOSTASIS MODEL ASSESSMENT OF BETA CELL FUNCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; LIPOPROTEIN BLOOD LEVEL; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET CELL; PANCREAS ISLET CELL FUNCTION; PANCREATITIS; PERSONALIZED MEDICINE; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; THYROID MEDULLARY CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON;

EID: 84865861808     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01342.x     Document Type: Review

References (96)

1. DeFronzo RA,. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009; 58: 773-795.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endoc Pract, 2009; 15: 540-559.
3. Pani LN, Nathan DM, Grant RW,. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care, 2008; 31: 386-390.
4. Ridderstrale M, Gudbjornsdottir S, Eliasson B, Nilsson PM, Cederholm J,. Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med, 2006; 259: 314-322.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009; 32: 193-203.
6. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, Macconell L,. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin, 2008; 24: 2943-2952.
7. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH,. Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab, 2011; 13: 982-989.
8. Baggio LL, Drucker DJ,. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007; 132: 2131-2157. (Pubitemid 46711096)
9. Nauck MA,. Unraveling the science of incretin biology. Am J Med, 2009; 122: S3-S10.
10. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006; 368: 1696-1705. (Pubitemid 46048557)
11. Kjems LL, Holst JJ, Volund A, Madsbad S,. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes, 2003; 52: 380-386. (Pubitemid 36173193)
12. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ,. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia, 2011; 54: 10-18.
13. Neumiller JJ, Campbell RK,. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother, 2009; 43: 1433-1444.
14. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem, 2000; 43: 1664-1669. (Pubitemid 30304999)
15. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 2004; 53: 1187-1194. (Pubitemid 38569002)
16. Deacon CF,. Therapeutic strategies based on glucagon-like peptide 1. Diabetes, 2004; 53: 2181-2189. (Pubitemid 39145569)
17. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm, 2005; 62: 173-181. (Pubitemid 40674548)
18. Kim D, Macconell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care, 2007; 30: 1487-1493. (Pubitemid 46871159)
19. Herman GA, Stevens C, Van DK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther, 2005; 78: 675-688. (Pubitemid 41773643)
20. Gallwitz B,. New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes Metab Syndr Obes, 2010; 3: 117-124.
21. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA,. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab, 2009; 11: 786-794.
22. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med, 2007; 146: 477-485. (Pubitemid 351650556)
23. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet, 2008; 372: 1240-1250.
24. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2008; 30: 1448-1460.
25. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009; 374: 39-47.
26. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A,. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab, 2009; 11: 1153-1162.
27. Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther, 2010; 12: 233-240.
28. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET)-a proof-of-concept study. Diabetes Care, 2010; 33: 1509-1515.
29. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC,. Effects of exenatide plus rosiglitazone on beta cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care, 2010; 33: 951-957.
30. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab, 2011; 96: 1301-1310.
31. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care, 2007; 30: 1608-1610. (Pubitemid 46871185)
32. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet, 2009; 373: 473-481.
33. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med, 2009; 26: 268-278.
34. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009; 32: 84-90.
35. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care, 2009; 32: 1224-1230.
36. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia, 2009; 52: 2046-2055.
37. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, 2010; 375: 1447-1456.
38. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet, 2010; 375: 2234-2243.
39. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet, 2010; 376: 431-439.
40. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin, 2008; 24: 537-550. (Pubitemid 351294402)
41. Scott R, Loeys T, Davies MJ, Engel SS,. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab, 2008; 10: 959-969.
42. Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab, 2010; 12: 252-261.
43. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I,. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/Metab Res Rev, 2010; 26: 540-549.
44. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract, 2010; 64: 562-576.
45. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab, 2010; 12: 167-177.
46. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab, 2011; 13: 160-168.
47. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin, 2011; 27: 1049-1058.
48. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R,. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract, 2009; 63: 1395-1406.
49. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care, 2009; 32: 1649-1655.
50. Hollander P, Li J, Allen E, Chen R,. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009; 94: 4810-4819.
51. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R,. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab, 2009; 11: 611-622.
52. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R,. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2009; 25: 2401-2411.
53. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I,. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract, 2010; 64: 1619-1631.
54. Chacra AR, Tan GH, Ravichandran S, List J, Chen R,. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res, 2011; 8: 150-159.
55. Hollander PL, Jia L, Frederich R, Allen E, Chen R,. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res, 2011; 8: 125-135.
56. Del PS, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA,. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab, 2011; 13: 258-267.
57. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA,. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes Obes Metab, 2011; 13: 653-661.
58. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab, 2011; 13: 65-74.
59. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care, 2010; 33: 1300-1303.
60. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open. European Association for the Study of Diabetes (Abstract).
61. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract, 2011; 65: 397-407.
62. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med, 2011; 28: 705-714.
63. Bunck MC, Diamant M, Eliasson B, et al. Exenatide affected circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care, 2010; 33: 1734-1737.
64. Henry RR, Smith SR, Schwartz SL, et al. Effects of saxagliptin on beta-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab, 2011; 13: 850-858.
65. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B,. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes, 2001; 50: 1562-1570. (Pubitemid 33639596)
66. Hui H, Nourparvar A, Zhao X, Perfetti R,. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology, 2003; 144: 1444-1455. (Pubitemid 36432086)
67. Perfetti R, Zhou J, Doyle ME, Egan JM,. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology, 2000; 141: 4600-4605. (Pubitemid 32055138)
68. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab, 2002; 283: E745-E752.
69. Knudsen LB,. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract, 2010; 64 (Suppl): 4-11.
70. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the GLP-1 receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink™ database. Diabetes Care, 2010; 34: 90-95.
71. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L,. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol, 2011; 10: 22.
72. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E,. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler, 2009; 15: 50-58.
73. Merck & Co I (2010) Januvia® (sitagliptin) tablets [prescribing information]. [Abstract]
74. Boehringer Ingelheim Pharmaceuticals I (2011) Tradjenta™ (linagliptin). [Abstract]
75. Bristol-Myers Squibb Company (2011) Onglyza® (saxagliptin) tablets [prescribing information]. [Abstract]
76. Desai S, Brinker A, Swann J, Iyasu S,. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med, 2010; 170: 1169-1171.
77. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract, 2010; 64: 984-990.
78. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC,. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141: 150-156.
79. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet, 2011; 50: 253-265.
80. Chacra AR,. Saxagliptin for type 2 diabetes. Diabetes Metab Syndr Obes, 2010; 3: 325-335.
81. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I,. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab, 2011; 13: 523-532.
82. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab, 2011; 13: 939-946.
83. Anonymous (2011) Victoza® (liraglutide [rDNA origin] injection), solution for subcutaneous use [prescribing information]. [Abstract] Princeton, NJ: Novo Nordisk Inc., 2011.
84. Amylin Pharmaceuticals I (2010) Byetta® (exenatide) injection [prescribing information]. [Abstract]
85. Davidson JA, Brett J, Falahati A, Scott D,. Mild renal impairment and the efficacy and safety of liraglutide. Endoc Pract, 2010; 17: 345-355.
86. Garber A, Marre M, Nauck M,. The efficacy of liraglutide is not impacted in subjects positive for anti-liraglutide antibodies: a pooled analysis. [Abstract] 2010.
87. Buse J, Montanya E, Brett J, et al. Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Diabetes, 2010; 59 (Suppl 1): A184-A185 (Abstract).
88. Noel RA, Braun DK, Patterson RE, Bloomgren GL,. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care, 2009; 32: 834-838.
89. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology, 2010; 151: 1473-1486.
90. Hegedus L, Moses AC, Zdravkovic M, Thi TL, Daniels GH,. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab, 2011; 96: 853-860.
91. Schernthaner G, Guerci B, Gallwitz B, et al. Impact of postprandial and fasting glucose concentrations on HbA(1c) in patients with type 2 diabetes. Diabetes Metab, 2010; 36: 389-394.
92. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract, 2007; 77: 280-285. (Pubitemid 46670411)
93. Linnebjerg H, Kothare PA, Skrivanek Z, et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med, 2006; 23: 240-245.
94. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med, 2011; 154: 1-10.
95. Bain SC, Devries JH, Seufert J, et al. Adding insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycaemia rate: 52 week results. [Abstract] European Association for the Study of Diabetes, 2011.
96. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med, 2008; 25: 1129-1131.